• The rise and rise of biotech stocks?  Friday, 16 Jan 2015 | 5:20 AM ET

    Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.

  • Biopharma's challenges in 2015  Wednesday, 14 Jan 2015 | 9:30 AM ET

    Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.

  • I am a better person: Sam Waksal  Tuesday, 13 Jan 2015 | 8:36 AM ET

    Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.

  • I'm not running the show: Sam Waksal  Tuesday, 13 Jan 2015 | 8:33 AM ET

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discusses his role in the company.

  • Sam Waksal's IPO biotech plans  Tuesday, 13 Jan 2015 | 8:31 AM ET

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discuss plans to take the biotech company public.

  • Biogen Idec beefs up pain pipeline  Monday, 12 Jan 2015 | 3:16 PM ET

    Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.

  • 23andMe partners with big pharma  Monday, 12 Jan 2015 | 12:20 PM ET

    Anne Wojcicki, co-founder and CEO of genetic-testing startup 23andMe, discusses the new deals with Pfizer and Genentech.

  • Celgene CEO: Creating a great future  Monday, 12 Jan 2015 | 11:45 AM ET

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.

  • Analyzing Eli Lilly's drug pipeline  Monday, 12 Jan 2015 | 10:15 AM ET

    CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.

  • Stock moving information kept behind doors  Thursday, 8 Jan 2015 | 2:37 PM ET

    CNBC's Meg Tirrell provides insight to the debate over transparency from biotech companies. Biotech investor Brad Loncar, thinks this is just an awareness issue.

  • Jim Cramer's top 10 biotech players  Tuesday, 6 Jan 2015 | 6:15 PM ET

    The biotechs were one of the best performing sectors for 2014. Can it work wonders for 2015? Cramer gives his top players in the biotech space.

  • Biotech's strong pipeline  Tuesday, 6 Jan 2015 | 5:45 PM ET

    A total of 71 biotech companies went public in 2014. Cowen Group President and Cowen & Company CEO Jeffrey Solomon, discusses the market sentiment toward the sector.

  • Will biotech bull run continue?  Tuesday, 6 Jan 2015 | 10:43 AM ET

    Discussing the outlook on the pharmaceutical sector, including leaders like Gilead and Celgene, with Michael Yee, RBC Capital Markets biotech analyst.

  • Gilead pops, AbbVie drops  Monday, 5 Jan 2015 | 2:50 PM ET

    Gilead Sciences is lifting the biotech sector higher in today's trade, reports CNBC's Meg Tirrell.

  • Biotech dips mid-year, then you buy: Pro  Wednesday, 31 Dec 2014 | 5:31 PM ET

    Biotech finished 2014 up 44 percent. David Seaburg, thinks biotech will outperform the S&P 500 this year, but there could be some suffering mid-year.

  • 'Mammoth' IPOs send momentum into 2015: Analyst Tuesday, 30 Dec 2014 | 12:54 PM ET

    IPO momentum should continue into 2015 after an active 2014 when huge offerings hit like "mammoths from the sky," an analyst said.

  • Want big results? Go small  Monday, 29 Dec 2014 | 10:25 AM ET

    CNBC's Dominic Chu takes a look at the biggest winners of the market rally and digs into the massive year-end surge for small caps.

  • Bullish on biotech  Monday, 29 Dec 2014 | 7:18 AM ET

    Eric Schmidt, Cowen & Company senior analyst, predicts the biotech sector will outperform the S&P 500 next year.

  • Mini rebound in biotechs  Wednesday, 24 Dec 2014 | 10:42 AM ET

    CNBC's Meg Tirrell provides insight to the selloff in biotech stocks after Express Scripts announced it will exclusively cover AbbVie's hepatitis C drug.

  • Behind the overnight slump in US biotech plays  Tuesday, 23 Dec 2014 | 10:24 PM ET

    Brewing price sensitivity in the sector, compounded with expensive valuations, led to the selloff in U.S. biotech stocks, says Peter Boockvar, Chief Market Analyst at The Lindsey Group.